Patients with a known history of congestive heart failure (CHF), cardiomyopathy, myocarditis, myocardial infarction (MI), exposure to cardiotoxic medications, or with a clinical history suggestive of the above must have an electrocardiography (EKG) and echocardiogram (ECHO) performed within  days prior to registration and as clinically indicated while on treatment
Patients with a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last  months)
Patients within  months of myocardial infarction (MI) and stroke will be excluded
Myocardial infarction (MI) within  months of Screening Visit.
No uncontrolled angina, congestive heart failure or myocardial infarction (MI) within  months
Myocardial infraction (MI) within the previous  months
Patient has history of uncontrolled angina, congestive heart failure or recent myocardial infarction (MI) within  months
Myocardial Infraction (MI) within the previous  months
History of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG) within  months prior to starting study treatment.
No uncontrolled angina, congestive heart failure or myocardial infraction (MI) within  months prior to registration on study
History of myocardial infarction (MI) or New York Heart Association (NYHA) Class II-IV congestive heart failure within  months of the administration of the first dose of ARQ  (MI occurring >  months of the first dose of ARQ  will be permitted); Grade  or worse conduction defect (e.g., right or left bundle branch block)
History of myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within  months of the first dose of ARQ  (MI that occurred >  months prior to the first dose of ARQ  will be permitted)
Myocardial infarction (MI) within  months.  Presence of active, uncontrolled infection.  Known central nervous system illness (e.g., Alzheimer's disease).
Patients with class III or greater congestive heart failure (CHF) or myocardial infarction (MI) within last  months
Subject has a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last  months)
Prior myocardial infraction (MI) ascertained from medical history and review of systems
Myocardial infarction (MI) within  months prior to the first dose of study drug;
Myocardial infarction (MI) within past  months before randomization
Myocardial infarction (MI) within the last  months
History of cardiovascular disease (e.g., myocardial infraction [MI], thrombotic or thromboembolic event in the last  months)
Myocardial infarction (MI) with ASCT or developed dilated cardiomyopathy with ASCT
History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within  months prior to study entry
History of myocardial infraction (MI) within  month prior to starting study treatment
Myocardial infarction (MI) within  months prior to the first dose of brigatinib
History of myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association classification within  months of the first dose of ARQ  (MI occurring > months of the first dose of ARQ  will be permitted)
No CVA within  months, no MI within  months
Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within  months of the first dose of ARQ  (MI that occurred >  months prior to the first dose of ARQ  will be permitted)
Uncontrolled angina, congestive heart failure or myocardial infarction (MI) within ( months)
Hemodynamically unstable patients (not in cardiogenic shock or having an acute myocardial infarction [MI])
History of myocardial infarction (MI) documented by elevated cardiac enzymes with persistent regional wall motion abnormality on assessment of left ventricular (LV) function (patients with history of MI must have an echocardiogram (echo) instead of/in addition to a MUGA to evaluate LV wall motion)
Recent history of myocardial infarction (MI) or symptomatic coronary artery disease within the preceding  months
Myocardial infarction (MI) within  months prior to first study drug administration
Subject has a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last  months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study
Myocardial infarction (MI) within  months prior to first study drug administration
Myocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than % secondary to a more remote MI.
History of myocardial infarction (MI) or NYHA Class II-IV congestive heart failure within  months of the administration of the first dose of ARQ  (MI occurring > months of the first dose of ARQ  will be permitted); Grade  or worse conduction defect (eg right or left bundle branch block); left ventricular ejection fraction (LVEF) < % assessed by echocardiogram/MUGA scan
Acute MI ?  months prior to dosing with study drug
Myocardial infarction (MI) within the prior  months
Acute Coronary Syndrome (ACS) (angina or MI) in last  months.
Active myocardial ischemia (acute ST elevation or non ST elevation myocardial infarction [MI])
Myocardial Infarction (MI) within  months
Myocardial infarction (MI) in the last  months
Previous history of angina pectoris or acute myocardial infarction (MI) within  months
no recent (past  months) cardiovascular trauma: MI, stroke
